Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 5/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812493 | 0.83 | NR3C1 (0.39) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL16812352 | 0.81 | PDE1B (0.38) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL16812354 | 0.81 | CDK5 (0.39) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL16812355 | 0.80 | ALDH1A1 (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1NR3C1 | |
| SCHEMBL24263381 | 0.80 | PDE1B (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1NR3C1 | |
| SCHEMBL16794653 | 0.79 | CNR2 (0.41) | CNR2ALDH1A1POLB | |
| SCHEMBL16794695 | 0.79 | TYK2 (0.44) | KMT2AMEN1CNR2NR3C1 | |
| SCHEMBL16794714 | 0.79 | TYK2 (0.49) | KMT2AMEN1CNR2NR3C1 | |
| SCHEMBL16794676 | 0.79 | PDE1B (0.40) | KMT2AMEN1SMN1; SMN2ALDH1A1NR3C1 | |
| SCHEMBL18161034 | 0.79 | PDE1B (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | KLKB1 679/4885CASR 4215/4885KMT2A 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.